Abstract
The present study investigated the possible clinical significance of serum CA125 levels in patients with non-Hodgkin's lymphoma (NHL) and the mechanism of secretion. Serum CA125 levels in 335 patients with NHL were measured by enzyme-linked immunosorbent assay. The tissue CA125 expression in 22 patients with NHL was performed on paraffin section by immunohistochemical methods. One hundred and ninety-eight cases (59.1%) were found to have elevated serum CA125 levels. Serum CA125 levels were associated with clinical stage, effusions, high serum lactate dehydrogenase and β2-M levels, and response to therapy. Microscopically, immunohistochemical staining revealed that malignant tumor cells demonstrated negative CA125 expression in all of the 22 cases. Our results suggested that serum CA125 levels could be an interesting tumor marker in NHL. The immunohistochemical study suggested that CA125 appeared not to be secreted by lymphoma cells directly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
